Sustained Release Therapies with the Prostaglandin Analogues Intracameral Implants
Abstract The travoprost intracameral implant was recently approved by the US Food and Drug Administration for sustained release medical treatment of open-angle glaucoma in the USA. The approval represents a substantial and progressive step forward in the area of sustained-release glaucoma therapy. T...
| Published in: | Ophthalmology and Therapy |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-05-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-024-00965-4 |
| Summary: | Abstract The travoprost intracameral implant was recently approved by the US Food and Drug Administration for sustained release medical treatment of open-angle glaucoma in the USA. The approval represents a substantial and progressive step forward in the area of sustained-release glaucoma therapy. Topical intraocular pressure-lowering medications for the treatment of glaucoma are faced with a host of challenges for long-term and usually lifelong care. A changing paradigm in glaucoma management involves first-line interventions with laser modalities, micro-invasive surgeries, and sustained-release treatment platforms. Future needs in the area of sustained-release therapy include a non-prostaglandin drug delivery platform and longer-term treatments that do not require surgical reintervention. |
|---|---|
| ISSN: | 2193-8245 2193-6528 |